CABALETTA BIO INC. -

Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201

02 10月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

19 9月 2023 08:00:00 条件 Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

30 8月 2023 08:00:00 条件 Nasdaq GlobeNewswire

Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201

22 8月 2023 08:00:00 条件 Nasdaq GlobeNewswire

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

10 8月 2023 07:00:01 条件 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the Jefferies Healthcare Conference

31 5月 2023 08:00:00 条件 Nasdaq GlobeNewswire

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

22 5月 2023 16:30:00 条件 Nasdaq GlobeNewswire

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

17 5月 2023 22:16:01 条件 Nasdaq GlobeNewswire

Cabaletta Bio Announces Proposed Public Offering of Common Stock

17 5月 2023 16:01:00 条件 Nasdaq GlobeNewswire

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

16 5月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update

11 5月 2023 07:00:01 条件 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

02 5月 2023 16:35:00 条件 Nasdaq GlobeNewswire

Cabaletta Bio Receives FDA Fast Track Designation for CABA-201

01 5月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

25 4月 2023 08:00:01 条件 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

13 4月 2023 16:30:00 条件 Nasdaq GlobeNewswire

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus

31 3月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

16 3月 2023 07:00:01 条件 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference

28 2月 2023 08:00:02 条件 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

05 1月 2023 08:00:01 条件 Nasdaq GlobeNewswire

Cabaletta Bio Announces $35 Million Offering

08 12月 2022 07:00:00 条件 Nasdaq GlobeNewswire